TY - JOUR T1 - Gynecologic Cancer InterGroup (GCIG) Consensus Review for Mullerian Adenosarcoma of the Female Genital Tract JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - S78 LP - S82 DO - 10.1097/IGC.0000000000000239 VL - 24 IS - Supp 3 AU - Michael Leonard Friedlander AU - Alan Covens AU - Rosalind M. Glasspool AU - Felix Hilpert AU - Gunnar Kristensen AU - Sanghoon Kwon AU - Frederic Selle AU - William Small AU - Els Witteveen AU - Peter Russell Y1 - 2014/11/01 UR - http://ijgc.bmj.com/content/24/Supp_3/S78.abstract N2 - Mullerian adenosarcomas of the female genital tract are rare malignancies, originally described in the uterus, the most common site of origin, but they may also arise in extrauterine locations. Uterine adenosarcomas make up 5% of uterine sarcomas and tend to occur in postmenopausal women. They are usually low-grade tumors and are characterized by a benign epithelial component with a malignant mesenchymal component, which is typically a low-grade endometrial stromal sarcoma but can also be a high-grade sarcoma. Tumors that exhibit a high-grade sarcomatous overgrowth have a worse outcome. Adenosarcomas have been described as being midway along the spectrum between benign adenofibromas and carcinosarcomas. They generally have a good prognosis with the exception of deeply invasive tumors or those with high-grade sarcomatous overgrowth. Extrauterine adenosarcomas also have a higher risk for recurrence. In view of their rarity, there have not been any clinical trials in mullerian adenosarcomas and relatively little research. This article reviews the current knowledge and provides recommendation for the management of mullerian adenosarcomas. ER -